课题基金 / 基金详情

Development of AAV vectors for long-term expression of eCD4-Ig

Development of AAV vectors for long-term expression of eCD4-Ig
开发用于长期表达 eCD4-Ig 的 AAV 载体
批准号:
9979748
负责人:
MICHAEL DAVID ALPERT
金额:
$99.94万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-01 至 2021-07-31

项目摘要

项目成果

MICHAEL DAVID ALPERT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT / SUMMARY / PROJECT DESCRIPTION A single intramuscular injection of an adeno-associated virus (AAV) vector that expresses eCD4-Ig has the potential to treat or prevent HIV-1 infection for a lifetime. eCD4-Ig is a synthetic antibody or “immunoadhesin” constructed by fusing parts of the viral receptor (CD4) and coreceptor (CCR5) to the constant region of an antibody. Because eCD4-Ig binds the HIV-1 envelope glycoprotein (Env) through the same contacts used by Env to recognize its receptor and coreceptor, eCD4-Ig neutralizes 100% of HIV-1 isolates and presents fundamental barriers to viral escape. We have previously shown that rhesus macaques inoculated with AAV expressing eCD4-Ig exhibited sterilizing protection against high-dose intravenous challenges with simian- human immunodeficiency virus (SHIV). Now, we propose several practical innovations designed to maximize the concentrations of eCD4-Ig in plasma that are sustained over the long term by AAV-transduced muscle.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites
  • 批准号:
    10867558
  • 项目类别:
  • 资助金额:
    $100.0万
  • 财政年份:
    2023
  • 负责人:
    MICHAEL DAVID ALPERT
  • 依托单位:
Process development for manufacturing eCD4-Ig
  • 批准号:
    10603836
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2023
  • 负责人:
    MICHAEL DAVID ALPERT
  • 依托单位:
Glycoengineering eCD4-Ig
  • 批准号:
    10589151
  • 项目类别:
  • 资助金额:
    $100.0万
  • 财政年份:
    2022
  • 负责人:
    MICHAEL DAVID ALPERT
  • 依托单位:
Glycoengineering eCD4-Ig
  • 批准号:
    10549884
  • 项目类别:
  • 资助金额:
    $97.47万
  • 财政年份:
    2022
  • 负责人:
    MICHAEL DAVID ALPERT
  • 依托单位:
海外基金